Formycon and OneSource Specialty Pharma Form Strategic Manufacturing Partnership for Biosimilars

Formycon AG (FSE: FYB) and OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) announced a strategic manufacturing partnership for biosimilars on July 14, 2026. Under the agreement, OneSource will serve as a strategic manufacturing partner for Formycon, providing integrated Drug Substance and Drug Product manufacturing capabilities from its biologics facility in Bangalore, India. The collaboration combines Formycon’s biosimilar development expertise with OneSource’s end-to-end biologics manufacturing capabilities to support Formycon’s biosimilar programs for global markets.

Dr. Stefan Glombitza, CEO of Formycon AG, stated: "Reliable, scalable and cost-efficient manufacturing is a cornerstone of our FYB4Growth strategy. By adding OneSource to our network of strategic manufacturing partners, we are further strengthening our supply capabilities with a partner that meets our unwavering commitment to high standards of quality, operational excellence and cost-efficiency. Together, we aim to broaden sustainable global access to life-changing biosimilar therapies." Neeraj Sharma, Managing Director & CEO of OneSource Specialty Pharma, said: "We are delighted to partner with Formycon, one of the world’s leading biosimilar developers with a proven track record of bringing high-quality biosimilars to global markets. This partnership brings together Formycon’s development expertise and OneSource’s integrated manufacturing capabilities to expand access to high-quality, affordable biologics for patients worldwide."

The partnership underscores the shared commitment of both companies to advancing global access to biosimilars through reliable, high-quality, and scalable manufacturing. It highlights the need for a sustainable, cost-effective manufacturing model—one that OneSource is specifically positioned to deliver. Formycon brings a strong track record in biosimilar development and commercialization, supported by an established portfolio and a robust pipeline. OneSource complements this with an integrated biologics platform spanning cell line development through commercial fill-finish, five manufacturing facilities approved by leading global regulatory authorities, including the US FDA and EMA, and extensive expertise across biologics, sterile injectables, and drug-device combinations.

Formycon’s FYB4Growth strategy is based on four strategic pillars: geographic diversification, a smart portfolio strategy, excellence and innovation, and consistent cost efficiency. This partnership aligns with the cost efficiency pillar by leveraging OneSource’s capabilities to streamline processes and enhance scalability. Formycon currently has three biosimilars on the market—FYB201/ranibizumab, FYB202/ustekinumab, and FYB203/aflibercept—and four pipeline candidates, including FYB206/pembrolizumab and FYB208/dupilumab. The collaboration with OneSource aims to support these programs and future developments.

OneSource, a pure-play global CDMO, focuses on complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies. With five state-of-the-art manufacturing facilities and a dedicated team of over 1,600 professionals, the company has won the trust of global pharmaceutical companies seeking efficient, end-to-end solutions. This partnership reinforces India’s position as a global hub for biologics development and manufacturing.